Becker K and Jones JJ
This review article informs the reader about daprodustat (GSK1278863), a novel oral therapeutic agent for the treatment of anemia currently in development by GlaxoSmithKline, inclusive of published and ongoing clinical trial information. Results from phase II studies have demonstrated a promising therapeutic alternative for chronic kidney disease (CKD) patients that may ultimately change future clinical practice.
